Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Sell
49
ASPHF Quote, Financials, Valuation and Earnings
Last price:
$8.48
Seasonality move
:
-1.95%
Day range:
$8.48 - $8.48
52-week range:
$5.42 - $10.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
50.23x
P/B ratio:
56.06x
Volume:
--
Avg. volume:
--
1-year change:
31.47%
Market cap:
$3.2B
Revenue:
$136.3M
EPS (TTM):
-$0.50
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Ascentage Pharma Group International Co., Ltd. has -- downside to fair value with a price target of -- per share.
ASPHF vs. S&P 500
-
Over the past 5 trading days, Ascentage Pharma Group International Co., Ltd. has overperformed the S&P 500 by 0.57% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ascentage Pharma Group International Co., Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ascentage Pharma Group International Co., Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Ascentage Pharma Group International Co., Ltd. reported revenues of --.
Earnings Growth
-
Ascentage Pharma Group International Co., Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ascentage Pharma Group International Co., Ltd. reported earnings per share of --.
Enterprise value:
3.1B
EV / Invested capital:
--
Price / LTM sales:
50.23x
EV / EBIT:
--
EV / Revenue:
57.38x
PEG ratio (5yr expected):
-2.41x
EV / Free cash flow:
-83.29x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$38M
Return On Assets:
-14.84%
Net Income Margin (TTM):
-297.08%
Return On Equity:
-109.51%
Return On Invested Capital:
-19.66%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-03-31 | 2017-03-31 | 2018-03-31 | 2017-03-31 | 2018-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $275.2K | $141.2K | |
| Gross Profit | -- | -- | -- | -$1.6K | -$363.3K | |
| Operating Income | -- | -- | -- | -$2.5M | -$7.2M | |
| EBITDA | -- | -- | -- | -$2.2M | -$6.7M | |
| Diluted EPS | -- | -- | -- | -$0.02 | -$0.01 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $247.2M | $278.4M | $242.7M | $270.2M | -- | |
| Total Assets | $372.5M | $452.9M | $402.3M | $427.5M | -- | |
| Current Liabilities | $30M | $91.4M | $88.6M | $146.6M | -- | |
| Total Liabilities | $148.2M | $322M | $319.5M | $320.7M | -- | |
| Total Equity | $224.3M | $130.8M | $82.7M | $106.8M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-03-31 | 2017-03-31 | 2018-03-31 | 2017-03-31 | 2018-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$3.1M | -$9.1M | |
| Cash From Investing | -- | -- | -- | -$27.3M | $28.1M | |
| Cash From Financing | -- | -- | -- | $6.3M | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
ASPHF
Sector
Market Cap
$3.2B
$27.1M
Price % of 52-Week High
79.62%
51.93%
Dividend Yield
0%
0%
Shareholder Yield
-6.41%
-1.63%
1-Year Price Total Return
31.47%
-15.41%
Beta (5-Year)
--
0.489
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.48
200-day SMA
Buy
Level
$7.59
Bollinger Bands (100)
Sell
Level
8.51 - 9.91
Chaikin Money Flow
Buy
Level
418
20-day SMA
Sell
Level
$8.48
Relative Strength Index (RSI14)
Sell
Level
35.59
ADX Line
Sell
Level
33.29
Williams %R
Sell
Level
0
50-day SMA
Sell
Level
$8.72
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
7.3K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.4429)
Sell
CA Score
(Annual)
Level (-2.9891)
Sell
Beneish M-Score
(Annual)
Level (-0.7016)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.5962)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Stock Forecast FAQ
In the current month, ASPHF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ASPHF average analyst price target in the past 3 months is --.
-
Where Will Ascentage Pharma Group International Co., Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ascentage Pharma Group International Co., Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Ascentage Pharma Group International Co., Ltd.?
Analysts are divided on their view about Ascentage Pharma Group International Co., Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ascentage Pharma Group International Co., Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Ascentage Pharma Group International Co., Ltd.'s Price Target?
The price target for Ascentage Pharma Group International Co., Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ASPHF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ascentage Pharma Group International Co., Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ASPHF?
You can purchase shares of Ascentage Pharma Group International Co., Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ascentage Pharma Group International Co., Ltd. shares.
-
What Is The Ascentage Pharma Group International Co., Ltd. Share Price Today?
Ascentage Pharma Group International Co., Ltd. was last trading at $8.48 per share. This represents the most recent stock quote for Ascentage Pharma Group International Co., Ltd.. Yesterday, Ascentage Pharma Group International Co., Ltd. closed at $8.48 per share.
-
How To Buy Ascentage Pharma Group International Co., Ltd. Stock Online?
In order to purchase Ascentage Pharma Group International Co., Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ASPHF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ASPHF
Sector
P/E ratio
--
23.89x
PEG ratio
-2.41x
-0.01x
P/B ratio
56.06x
1.82x
Price / LTM sales
50.23x
1.60x
Growth Metrics
ASPHF
Sector
Revenue growth
--
4.35%
Earnings growth
--
9.95%
Revenue (5-year growth)
130.37%
6.41%
Earnings forecast
--
-$0.18
Profitability
ASPHF
Sector
Profitability FY 2024
$120.4M
$3.4M
Return on invested capital
-19.66%
-32.69%
Return on assets
-14.84%
-29%
Return on equity
-109.51%
-38.43%
Earnings Date
Last Earnings Date
Aug
20
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Nov
19
Balance Sheet
ASPHF
Sector
Total cash
$172.8M
$25.7M
Short term investments
--
$25.5M
Total assets
$359.6M
$75.6M
Long term debt
--
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
53
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
80
BNR alert for Jan 15
Burning Rock Biotech Ltd. [BNR] is up 18.69% over the past day.
Sell
37
TCOM alert for Jan 15
Trip.com Group Ltd. [TCOM] is down 2.31% over the past day.
Sell
39
DAVE alert for Jan 15
Dave, Inc. [DAVE] is up 3.48% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
